AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.

Rinvoq (upadacitinib) is a prescription drug that works to treat certain inflammatory conditions by decreasing the activity of immune system cells. Your response to this drug may vary based on ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

(American Journal of Gastroenterology) Real-world data confirmed the effectiveness of upadacitinib (Rinvoq) in Crohn's disease, with clinical remission achieved in 56% of patients at 6 months ...

Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly ...

Rinvoq is also approved for atopic dermatitis in Russia, Saudi Arabia, United Arab Emirates, New Zealand and Chile. The drug and another new immunology product – IL-23 inhibitor Skyrizi ...